Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,053 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: bleach bath (sodium hypochlorite); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Psoriasis, Atopic Dermatitis
Interventions: Pandel Cream 0.1%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 3 Months and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Atopic Dermatitis
Interventions: Online Teledermatology Care, Conventional in Office Care; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 4 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hereditary Angioedema (HAE), Angioedema
Interventions: Lanadelumab 150 mg, Lanadelumab 300 mg; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years and older
U.S. locations: 14
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Matching placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 33
States / cities: Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more

Conditions: Mild to Moderate Atopic Dermatitis
Interventions: Online Treatment response, EUCRISA; Behavioral · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 64 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Dermatitis, Allergy, Contact Allergy
Interventions: NeoMatriX Collagen Dressing; Device
Lead sponsor: NeXtGen Biologics, Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fairfield, New Jersey

Conditions: Atopic Dermatitis
Interventions: Itch CBT; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Q301 Cream, Vehicle; Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide, Phosphate Buffer Saline (PBS),; Drug
Lead sponsor: Shire; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Wheaton, Maryland

Conditions: Photoallergy
Interventions: SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Pinellas Park, Florida

Conditions: Hereditary Angioedema
Interventions: Inapplicable; Other
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions: Naltrexone, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pruritus, Atopic Dermatitis
Interventions: Aurstat Anti-Itch Hydrogel (Aurstat); Drug
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 12 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant, Placebo; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Little Rock, Arkansas • San Diego, California • Santa Monica, California + 3 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 160
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more

Conditions: Atopic Dermatitis
Interventions: Placebo, ZPL389 3mg, ZPL389 10mg, ZPL389 30mg, ZPL389 50mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Fountain Valley, California • San Diego, California + 7 more

Conditions: Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Interventions: Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more

Conditions: Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 80 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more

Conditions: Acne Vulgaris
Interventions: Tazarotene (Patch application in Challenge Phase); Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: vorinostat, laboratory biomarker analysis, biopsy, F-18 16 alpha-fluoroestradiol, positron emission tomography, anastrozole, letrozole, exemestane, gene expression analysis; Drug · Other · Procedure + 2 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Bleach Bath Treatment of Adults With Atopic Dermatitis

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Investigating Participation Patterns of Patients in Atopic Dermatitis Clinical Trials

Comparison Between Asynchronous Online Care Model With Usual In Office Care for the Management of Atopic Dermatitis

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Eucrisa for Atopic Dermatitis

Human Repeated Insult Patch Test

Brief Cognitive Behavioral Therapy to Treat Itch Rumination "Itch CBT" in Eczema

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

To Test for Photo Allergy Reaction of Sunscreens

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

NATIENS: Optimal Management and Mechanisms of SJS/TEN

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy